Item 8.01 Other Events As previously reported, as of March 31, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) had $107.1 million of cash and cash equivalents. Subsequent to March 31, 2026, in April and May 2026, the Company received approximately $28.7 million in proceeds from the exercise of common stock warrants. As of June 2, 2026, the Company had 196,632,574 shares of common stock outstanding.
SLS Sellas Life Sciences Group, Inc. - 8-K
Accession
0001104659-26-0692518.019.01
Item 8.01 - Other Events
66 words
Item 9.01 - Financial Statements and Exhibits
24 words
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3